José Costa

Director, Musculoskeletal Tumor Program at Yale Cancer Center

José Costa

José Costa

Director, Musculoskeletal Tumor Program at Yale Cancer Center

Biography

Jose Costa MD, FACP

Professor of Pathology and of Medicine (Medical Oncology); Director, Translational Diagnostics; Director, Musculoskeletal Tumor Program

Departments & Organizations

Biological and Biomedical Sciences (BBS): Molecular Medicine, Pharmacology, and Physiology

Yale Medical Group

Cancer Center, Yale: Sarcoma Oncology Program

Skin Diseases Research Center, Yale

Pathology: Surgical Pathology: Bone and Soft-tissue Pathology; Genitourinary Pathology | Molecular Diagnostics | Pathology Research

Molecular Diagnostics

Gene Regulation and Functional Genomics
Research Interests

Oncology; Carcinogenesis; Tumor development and progression; Advanced diagnostics; Molecular diagnostics; Diagnosed genetic alterations in tumors; Cancer risk detection by mutational load distribution analysis more...
Education

M.D., University of Barcelona, 1967

Selected Publications

Costa, J., Gonzalez-Garcia, I., and Sole, R. (2006). Spatial Dynamics in Cancer, in Complex Systems Science in Biomedicine (Deisboeck, T.S., and Kresh, J.Y.), Chapter 6.2, pp. 557-572.
Lage, J.M., et al. (2003). Whole genome analysis of genetic alterations in small DNA samples using hyperbranched strand displacement amplification and array-CGH. Genome Res. 13:294-307.
Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, Costa J, Robbins R, Burrow GN, Rosai J. (1998) Detection of thyroglobulin, thyroid peroxidase, and RET/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease. Journal of Clinical Pathology, Vol 16(3): 1158-1166.

Overview
RelSci Relationships

59

Number of Boards

2

Relationships
RelSci Relationships are individuals José Costa likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Aureon Biosciences, Inc.

Relationship likelihood: Strong

Professor at Icahn School of Medicine at Mount Sinai

Relationship likelihood: Strong

President-Research & Development at AAIPharma, Inc.

Relationship likelihood: Strong

Director at Yale Cancer Center

Relationship likelihood: Strong

Chief Executive Officer at VCN Biosciences SL

Relationship likelihood: Strong

Member, Scientific Advisory Board at VCN Biosciences SL

Relationship likelihood: Strong

Member, Scientific Advisory Board at VCN Biosciences SL

Relationship likelihood: Strong

Director at Aureon Biosciences, Inc.

Relationship likelihood: Strong

Former Co-Director of Drug Development & Gastrointestinal Oncology at Johns Hopkins University

Relationship likelihood: Strong

Co-Founder at New Leaf Venture Partners LLC

Relationship likelihood: Strong

Paths to José Costa
Potential Connections via
Relationship Science
You
José Costa
Director, Musculoskeletal Tumor Program at Yale Cancer Center
Career History
Director
Current

Aureon Biosciences, Inc. designs and develops prognostic tests. The company’s prognostic tests include Prostate Px, which assists physicians as they counsel patients on the range of possible treatment options, as well as the patient’s probability of disease recurrence, disease progression and Post-Op Px, a prognostic test to provide patients and their physicians with information about treatment options. The company was founded by Carlos Cordon-Cardo in 2002 and is headquartered in Yonkers, NY.

Director, Musculoskeletal Tumor Program
Current

Yale Cancer Center operates as a cancer center. It offers cancer immunology, cancer prevention and control, developmental therapeutics, genomics, genetics and epigenetics, radiobiology and radiotherapy, signal transduction, virus and other infection-associated cancers programs. The company was founded in 1974 and is headquartered in New Haven, CT.

Boards & Committees
Director
Current

Aureon Biosciences, Inc. designs and develops prognostic tests. The company’s prognostic tests include Prostate Px, which assists physicians as they counsel patients on the range of possible treatment options, as well as the patient’s probability of disease recurrence, disease progression and Post-Op Px, a prognostic test to provide patients and their physicians with information about treatment options. The company was founded by Robert H. Singer, Charles M. Cohen, Jonathan Edelson, Olivier Saidi and Carlos Cordón-Cardó in 2001 and is headquartered in Yonkers, NY.

Member, Scientific Advisory Board
Current

VCN Biosciences SL is a Spanish private company located in Barcelona that provides cancer treatment research and development services.

Investments
Details Hidden

Aureon Biosciences, Inc. designs and develops prognostic tests. The company’s prognostic tests include Prostate Px, which assists physicians as they counsel patients on the range of possible treatment options, as well as the patient’s probability of disease recurrence, disease progression and Post-Op Px, a prognostic test to provide patients and their physicians with information about treatment options. The company was founded by Carlos Cordon-Cardo in 2002 and is headquartered in Yonkers, NY.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by José Costa. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of José Costa's profile does not indicate a business or promotional relationship of any kind between RelSci and José Costa.